Research Article| Volume 17, ISSUE 2, P113-122, September 1993

Effects of oophorectomy and hormone replacement therapy on plasma lipids

      This paper is only available as a PDF. To read, Please Download here.


      The aim of this study was to determine the effects on plasma lipids and lipoproteins of oophorectomy and various hormone replacement therapy (HRT) delivery systems using low doses of medroxyprogesterone acetate (MPA, 2.5 mg/day). A total of 90 women completed the l-year follow-up period. Patients were randomly assigned to five groups. The first (n = 16) received 0.625 mg/day conjugated equine oestrogens (CEE) cyclically, the second (n = 20) 50 μg/day transdermal oestradiol cyclically and the third (n = 15) 0.625 mg/day CEE continuously. These three groups also received 2.5 mg MPA sequentially for the last 12 days of HRT administration. The fourth group (n = 20) received 0.625 mg/day CEE and 2.5 mg/day MPA continuously, while the fifth (n = 19) constituted a treatment-free control group. After oophorectomy patients showed increases in low-density lipoprotein (LDL), apolipoprotein B and the atherogenic index, whereas after HRT patients exhibited falls in plasma LDL, apolipoprotein B and the atherogenic index and increases in high-density lipoprotein (HDL) and apolipoprotein A1. No significant changes in total cholesterol were observed after surgery or treatment and decreased levels of triglycerides were detected only in the transdermal treatment group.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gordon T
        • Kannel WB
        • Hjortland MC
        • McNamara PM
        Menopause and coronary heart disease: The Framingham Study.
        Ann Intern Med. 1978; 89: 157-161
        • Castelli W
        Epidemiology of coronary heart disease: The Framingham Study.
        Am J Med. 1984; 76: 4-12
        • Hazzard WR
        Estrogen replacement and cardiovascular disease: serum lipids and blood pressure effects.
        Am J Obstet Gynecol. 1989; 161 (Suppl): 1847-1853
        • Campos H
        • McNamara JR
        • Wilson PWF
        • Ordovas JM
        • Schaefer EJ
        Differences in low density lipoprotein subfractions andapolipoproteins in premenopausal and postmenopausal women.
        J Clin Endocrinol Metab. 1988; 67: 30-35
        • Kapplan NM
        Estrogen replacement therapy: effect on blood pressure and other cardiovascular risk factors.
        J Reprod Med. 1985; 39 (Suppl): 802-803
        • Colditz GA
        • Willet WC
        • Stampfer MJ
        • Rosner B
        • Speizer FE
        • Hennekens CH
        Menopause and the risk of coronary heart disease in women.
        N Engl J Med. 1987; 316: 1105-1110
        • Lindquist O
        Influence of the menopause on ischaemic heart disease and its risk factors and on bone mineral content.
        Acta Obstet Gynecol Scand. 1990; 110 (Suppl): 17-21
        • Stampfer MJ
        • Willett WC
        • Colditz GA
        • Rosner B
        • Speizer FE
        • Hennekens CH
        A prospective study of postmenopausal estrogen therapy and coronary heart disease.
        N Engl J Med. 1985; 313: 1044-1049
        • Knopp R
        The effects of postmenopausal estrogen therapy on theincidence of arteriosclerotic vascular disease.
        Obstet Gynecol. 1988; 72 (Suppl): 18-22
        • Luciano AA
        • Turksoy RN
        • Carleo J
        • Hendrix JW
        Clinical and metabolic responses of menopausal women to sequential versus continuous estrogen and progestin replacement therapy.
        Obstet Gynecol. 1988; 71: 39-43
        • Friedewald WT
        • Levy RI
        • Fredrickson DS
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
        Clin Chem. 1972; 18: 499-502
        • Kannel WB
        • Hjortland MC
        • McNamara PM
        • Gordon T
        Menopause andrisk of cardiovascular disease: The Framingham Study.
        Ann Intern Med. 1976; 85: 447
        • Hjortland MC
        • McNamara PM
        • Kannel WB
        Some atherogenic concomitants of menopause: The Framingham Study.
        Am J Epidemiol. 1976; 103: 304-307
        • Rosenberg L
        • Hennekens HC
        • Rosner B
        • Belanger C
        • Rothman KJ
        • Speizer FE
        Early menopause and the risk of myocardial infarction.
        Am J Obstet Gynecol. 1981; 139: 47-51
        • Johansson BW
        • Kaij L
        • Kullander S
        • Lennier HC
        • Svanberg L
        • Astedt B
        On some late effects of bilateral oophorectomy in the age range 15–30 years.
        Acta Obstet Gynecol Scand. 1975; 54: 449-461
        • Bain C
        • Willett W
        • Hennekens CH
        • Rosner B
        • Belanger C
        • Speizer FE
        Use of postmenopausal hormones and risk of myocardial infarction.
        Circulation. 1981; 64: 42-46
        • Bengtsson C
        Ischaemic heart disease in women: a study based on a randomized population sample of women with myocardial infarction in Göteberg, Sweden.
        Acta Med Scand. 1973; 549 (Suppl.): 1-128
        • Castelo-Branco C
        • Celades M
        • González-Merlo J
        Lipoproteinas y perfil hormonal en mujeres menopáusicas sometidas a distintos esquemas de tratamiento con estrógenos y gestágenos.
        Acta Ginecol. 1990; 47: 95-100
        • Jensen J
        • Riis B
        • Strøm V
        • Nilas L
        • Christiansen C
        Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women.
        Am J Obstet Gynecol. 1987; 156: 66-71
        • Riis BJ
        • Johansen J
        • Christiansen C
        Continuous oestrogen-progestogen treatment and bone metabolism in postmenopausal women.
        Maturitas. 1988; 10: 51-58
        • Riis BJ
        • Thompsen K
        • Strom V
        • et al.
        The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss.
        Am J Obstet Gynecol. 1987; 156: 61-65
        • Place VA
        • Powers M
        • Darley PE
        • et al.
        A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms.
        Am J Obstet Gynecol. 1985; 152: 1092-1099
        • LaRosa JC
        Effect of estrogen replacement therapy on lipids: implications for cardiovascular risk.
        J Reprod Med (Suppl.). 1985; 30: 811-813
        • Ottosson VB
        Oral progesterone and estrogen-progestogen therapy: effects of natural and synthetic hormones in subfractions of HDL cholesterol and liver proteins.
        Acta Obstet Gynecol Scand (Suppl.). 1984; 127: 5-37
        • Selby PL
        • Peacock M
        Dose dependent response of symptoms, pituitary and bone to transdermal oestrogen in postmenopausal women.
        Br Med J. 1986; 293: 1337-1339
        • Williams SR
        • Frenchek B
        • Speroff T
        • Speroff L
        A study f combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement.
        Am J Obstet Gynecol. 1990; 162: 438-446
        • Christiansen C
        • Christensen MS
        • Grande P
        • Transbøl I
        Low-risk lipoprotein pattern in postmenopausal women on sequential oestrogen-progestogen treatment.
        Maturitas. 1984; 5: 193-199
        • Punnonen R
        • Rauramo -L
        Effect of bilateral oophorectomy and peroral estradiol valerate therapy on serum lipids.
        Int J Gynecol Obstet. 1976; 14: 13-16
        • Montgomery JC
        • Crook D
        • Godsland IF
        • Wynn V
        • Studd JW
        Plasma lipid risk factors in oophorectomized women.
        Br J Obstet Gynaecol. 1989; 96: 1236-1238
        • Cano A
        • Fernandes H
        • Serrano S
        • Mahiques P
        Effect of continuous oestradiol - medroxyprogesterone administration on plasma lipids and lipoproteins.
        Maturitas. 1991; 13: 35-42
        • Jensen J
        • Riis BJ
        • Stran V
        • Christiansen C
        Long-term and withdrawal effects of two different oestrogen-progestogen combinations on lipid and lipoprotein profiles in postmenopausal women.
        Maturitas. 1989; 11: 117-128
        • Sharf M
        • Ettinger M
        • Lanir A
        • Kahana L
        • Yeshurun D
        Lipid and lipoprotein levels following pure estradiol implantation in post-menopausal women.
        Gynecol Obstet Invest. 1985; 19: 207-212
        • Sonnendecker EW
        • Polakow ES
        • Benade AJ
        • Simchowitz E
        Serum lipoprotein effects of conjugated estrogen and a sequential conjugated estrogen-medrogestone regimen in hysterectomized postmenopausal women.
        Am J Obstet Gynecol. 1989; 160: 1128-1134
        • Stanczyk FZ
        • Shoupe D
        • Nunez V
        • Macias-Gonzáles P
        • Vijod MA
        • Lobo RA
        A randomized comparison of nonoral estradiol delivery in postmenopausal women.
        Am J Obstet Gynecol. 1988; 159: 1540-1546
      1. Duenas JL, Navarro J. Sindrome climatérico. Resultados de la terapéutica hormonal sustitutiva. Servicios de información cientifica de Schering España, S.A.